Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
L
Lineage Cell Therapeutics Inc
F:BT3
Lineage Cell Therapeutics Inc
F:BT3
Price:
0.794
EUR
0.76%
Market Cap:
€149.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
Sino Harbour Holdings Group Ltd
HKEX:1663
|
CN |
|
C
|
Charles Schwab Corp
BMV:SCHW
|
US |
|
A
|
Adhi Karya (Persero) Tbk PT
XMUN:KM6
|
ID |
|
A
|
AppliCAD PCL
SET:APP
|
TH |
|
InfuSystem Holdings Inc
F:1TZ
|
US |
|
Eat Well Investment Group Inc
F:6BC0
|
CA |
|
Astra International Tbk PT
F:ASJA
|
ID |
|
N
|
Newpath Resources Inc
CNSX:PATH
|
CA |
|
Alfa Energi Investama Tbk PT
IDX:FIRE
|
ID |
|
Dataproces Group A/S
CSE:DATA
|
DK |
|
Asseco Business Solutions SA
F:9QQ
|
PL |
|
Matador Partners Group AG
F:SQL
|
CH |
|
Modulight Oyj
F:78W
|
FI |
|
Cannabix Technologies Inc
F:8CT
|
CA |
|
Molecule Holdings Inc
F:ERV2
|
CA |
|
T
|
Teixeira Duarte SA
XMUN:TXC2
|
PT |
Wall St Price Targets
BT3 Price Forecast
Based on 8 analysts
Based on 8 analysts
+399% Upside
from
€0.794
today
Lineage Cell Therapeutics Inc (BT3)’s 12-month stock price forecast through October 2027 has a consensus target of €3.961, implying 399% upside. The forecast is based on price targets from 8 Wall Street analysts.
Lineage Cell Therapeutics Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
3.961
EUR
3.961
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 3.961 EUR with a low forecast of 2.615 EUR and a high forecast of 8.156 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
74%
Over the last 1 year, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 74%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
74%
Over the last 1 year, the compound annual growth rate for Gross Profit has been 57%. The projected CAGR for the next 8 years is 74%.